RXRX: AI-driven drug discovery platform delivers first-in-class assets and major partnership milestones
The company has transformed into an end-to-end AI-driven drug discovery leader, achieving significant cost reductions and clinical progress with first-in-class assets like REC-4881 and REC-1245. Strategic partnerships with Genentech and Sanofi have generated over $525 million in milestones, while a…